<code id='3F5D173F29'></code><style id='3F5D173F29'></style>
    • <acronym id='3F5D173F29'></acronym>
      <center id='3F5D173F29'><center id='3F5D173F29'><tfoot id='3F5D173F29'></tfoot></center><abbr id='3F5D173F29'><dir id='3F5D173F29'><tfoot id='3F5D173F29'></tfoot><noframes id='3F5D173F29'>

    • <optgroup id='3F5D173F29'><strike id='3F5D173F29'><sup id='3F5D173F29'></sup></strike><code id='3F5D173F29'></code></optgroup>
        1. <b id='3F5D173F29'><label id='3F5D173F29'><select id='3F5D173F29'><dt id='3F5D173F29'><span id='3F5D173F29'></span></dt></select></label></b><u id='3F5D173F29'></u>
          <i id='3F5D173F29'><strike id='3F5D173F29'><tt id='3F5D173F29'><pre id='3F5D173F29'></pre></tt></strike></i>

          focus

          focus

          author:hotspot    Page View:8923
          Adobe

          Venture firms backing health tech startups are telegraphing cautious optimism for 2024, advising startups to expect smaller and fewer checks as well as possible market consolidation but not to abandon hope just yet as investments stabilize following a sharp drop-off.

          As customers — often health systems, payers, or employers — and backers plot how they’ll invest shrinking budgets, they’re increasingly savvy about metrics, investors told STAT. They’re also less interested in rapid growth, and more keen on startups that can demonstrate savings and efficiency.

          advertisement

          That’s a sharp contrast from the unrestrained health tech investments that peaked in 2021, fueled by a pandemic-era frenzy for virtual appointments, mental health care and app-based therapies.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          ChatGPT in medicine: STAT answers readers' burning questions
          ChatGPT in medicine: STAT answers readers' burning questions

          MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

          read more
          CDC says it’s too soon to assess risk posed by Covid subvariant
          CDC says it’s too soon to assess risk posed by Covid subvariant

          Anursepreparesadoseofthispastspring'sCovid-19boostershot.JacobKing/WPAPoolviaGettyImagesTheCentersfo

          read more
          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more

          'Null' research findings aren't empty of meaning. Let's publish them

          APStockEverymedicalresearcherdreamsofdoingstudiesorconductingclinicaltrialsthatgenerateresultssocomp